Sponsor

Advaxis, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Advaxis, Inc. appears in 5 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials5
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

5 shown
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung CancerNCT03847519 · lead sponsor · 2019-02-12
COMPLETED
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction ChemotherapyNCT02531854 · lead sponsor · 2018-12-01
WITHDRAWN
A Study of ADXS-NEO Expressing Personalized Tumor AntigensNCT03265080 · lead sponsor · 2018-03-28
TERMINATED
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT02325557 · lead sponsor · 2015-06-04
COMPLETED
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerNCT02164461 · lead sponsor · 2015-03-04
COMPLETED

Sponsor roles

lead sponsor5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.